Zealand Pharma A/S (ZLDPF) Stock Price, News & Analysis

Company Overview

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon that is in Phase III clinical trials for treating congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.

Key Stats

• Today's Range: $67.62 to $69.00
• 50-Day Range: $58.87 to $83.52
• 52-Week Range: $57.97 to $141.74
• Volume: 252 shs
• Average Volume: 914 shs
• Market Capitalization: $4.80 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Strong Buy

ZLDPF Stock Analysis - Frequently Asked Questions

How have ZLDPF shares performed this year?

Zealand Pharma A/S's stock was trading at $102.36 at the beginning of 2025. Since then, ZLDPF stock has decreased by 33.9% and is now trading at $67.6240.
View the best growth stocks for 2025 here.

How were Zealand Pharma A/S's earnings last quarter?

Zealand Pharma A/S (OTCMKTS:ZLDPF) announced its quarterly earnings data on Thursday, May, 8th. The company reported ($0.67) EPS for the quarter, topping the consensus estimate of ($0.77) by $0.10. The firm had revenue of $1.14 million for the quarter, compared to analysts' expectations of $248.61 million. Zealand Pharma A/S had a negative net margin of 1,725.03% and a negative trailing twelve-month return on equity of 15.24%.

How do I buy shares of Zealand Pharma A/S?

Shares of ZLDPF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 5/08/2025
• Today: 5/28/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Private households
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:ZLDPF
• Previous Symbol: NASDAQ:ZLDPF
• CIK: 2068427
• Web: www.zealandpharma.com
• Phone: 45-8877-3600
• Fax: 45-8877-3898
• Employees: 340
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($2.49)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$102.18 million
• Net Margins: -1,725.03%
• Pretax Margin: -1,383.25%
• Return on Equity: -15.24%
• Return on Assets: -13.77%

Debt

• Debt-to-Equity Ratio: 0.03
• Current Ratio: 35.49
• Quick Ratio: 35.49

Sales & Book Value

• Annual Sales: $9.09 million
• Price / Sales: 541.63
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.49 per share
• Price / Book: 15.44

Miscellaneous

• Outstanding Shares: 71,024,000
• Free Float: N/A
• Market Cap: $4.92 billion
• Optionable: Not Optionable
• Beta: 0.92